In the March 2017 issue, the piece “A protein puzzle: Untangling the mysterious condition of amyloidosis” (Nat. Med. 23, 266–269, 2017) incorrectly stated that the FDA placed Ionis' NEURO-TTR trial on hold. The FDA had placed a related trial called CARDIO-TTR on hold after some patients in the NEURO-TTR trial developed complications. The error has been corrected in the HTML and PDF versions of this article.
The online version of the original article can be found at 10.1038/nm0317-266
About this article
Cite this article
Correction. Nat Med 23, 404 (2017). https://doi.org/10.1038/nm0417-404